Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
Type:
Grant
Filed:
April 12, 2010
Date of Patent:
October 6, 2015
Assignee:
The Johns Hopkins University
Inventors:
Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
Abstract: The present invention relates to Human Immunodeficiency Virus-1 (HIV-1) Group P of the strain designated 06CMU14788 and fragments thereof, primers which are derived from HIV-1 Group P, immunogenic regions thereof, immunoassays and nucleic acid based assays for the detection of Human Immunodeficiency Virus (HIV) that employ said HIV-1 Group P or fragments thereof and therapeutic compositions containing said HIV-1 Group P or fragments thereof.
Type:
Grant
Filed:
February 16, 2011
Date of Patent:
October 6, 2015
Assignee:
ABBOTT LABORATORIES
Inventors:
Catherine A. Brennan, Vera Holzmayer, Anadruzela S. Vallari, Julie Yamaguchi
Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
Abstract: The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.
Type:
Grant
Filed:
October 12, 2011
Date of Patent:
September 22, 2015
Assignee:
GlaxoSmithKline Biologicals, S.A.
Inventors:
Nathalie Garcon, Moncef Mohamed Slaoui, Christian Van Hoecke
Abstract: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.
Abstract: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line and/or by the reduction of endosomal-lysosomal system acidification.
Type:
Grant
Filed:
July 28, 2009
Date of Patent:
September 1, 2015
Inventors:
Hans Nauwynck, Gerald Misinzo, Sven Arnouts
Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus H5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
August 25, 2015
Assignees:
Temasek Life Sciences Laboratory Limited, National Institute of Health Research and Development (NIHRD)-Ministry of Health of the Republic of Indonesia
Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.
Type:
Grant
Filed:
December 24, 2004
Date of Patent:
August 18, 2015
Assignee:
De Staat der Nederlanden, Vert. Door de Minister Van VWS
Inventors:
Willem Luytjes, Myra Noorely Widjojoatmodjo
Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Type:
Grant
Filed:
January 8, 2015
Date of Patent:
August 18, 2015
Assignee:
ADMA BIOLOGICS, INC.
Inventors:
Adam S. Grossman, James Mond, Jerrold B. Grossman
Abstract: The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
August 11, 2015
Assignee:
Zoetis Services LLC
Inventors:
Jay Gregory Calvert, Shelly Shields, David E. Slade, Siao-Kun Welch
Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.
Abstract: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from Newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus. A vaccine based on this recombinant npMDV can be used to induce in poultry a protective immune response not only against Marek's disease, but also against Newcastle disease and Infectious bursal disease. The invention also relates to methods and uses involving the recombinant npMDV, expression cassette, infected host cells, and vaccines.
Type:
Grant
Filed:
October 19, 2012
Date of Patent:
August 4, 2015
Assignee:
Intervet, Inc.
Inventors:
Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
August 4, 2015
Assignee:
MedImmune, LLC
Inventors:
Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
Abstract: The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided.
Type:
Grant
Filed:
July 20, 2009
Date of Patent:
August 4, 2015
Assignee:
National Health Research Institutes
Inventors:
Yen-Hung Chow, Hsiao-Yun Shao, Charles Sia, Pele Chong
Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
Type:
Grant
Filed:
August 16, 2012
Date of Patent:
July 28, 2015
Assignee:
Imperial Innovations Limited
Inventors:
Donna Elizabeth Davies, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3?untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5?direction as far as the 5?boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
Type:
Grant
Filed:
December 3, 2012
Date of Patent:
July 28, 2015
Assignee:
The United States of America, as represented by the Secretary of the Department of Health & Human Services
Inventors:
Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
Abstract: The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORF1 that encodes the nsp2 polypeptide.
Type:
Grant
Filed:
October 19, 2011
Date of Patent:
July 14, 2015
Assignee:
University of Minnesota
Inventors:
Kay S. Faaberg, Jun Han, Gongping Liu, Yue Wang
Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
July 14, 2015
Assignee:
ALPHAVAX, INC.
Inventors:
Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
Abstract: The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.